GCM
CMPX icon

Graham Capital Management’s Compass Therapeutics CMPX Stock Holding History

Graham Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$125K Sell
23,551
-29,876
-56% -$172K ﹤0.01% 1014
2025
Q4 		$287K Buy
+53,427
New +$247K 0.01% 877

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Graham Capital Management's CMPX Position: Q1 2026 in Review

Graham Capital Management reduced its Compass Therapeutics (CMPX) stake by 56% in Q1 2026, selling an estimated $172K and leaving 23,551 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Graham Capital Management first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $287K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Graham Capital Management held 23,551 shares of Compass Therapeutics worth $125K as of Q1 2026.
  • Graham Capital Management sold 29,876 Compass Therapeutics shares in Q1 2026, an estimated $172K.
  • Compass Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1014 holding.
  • Graham Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Graham Capital Management's Compass Therapeutics position peaked at $287K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.